Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 4/2024

30.11.2023 | Oncology

Angiographic characteristics and treatment approach in patients undergoing intra-arterial chemotherapy for retinoblastoma

verfasst von: Alexander M. Rusakevich, Michael I. Nahhas, Brenda Zhou, Mark J. Dannenbaum, Maria E. Bretana, Amy C. Schefler

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify the specific clinical and angiographic variables that determine the success of intra-arterial chemotherapy (IAC) in a patient with retinoblastoma.

Methods

Medical records from patients undergoing intra-arterial chemotherapy for the treatment of retinoblastoma between January 2015 and June 2020 within a large academic ocular oncology practice were retrospectively reviewed. Demographics were recorded together with clinical, ocular, and angiographic variables such as the diameter of the ophthalmic artery (OA), angle of ophthalmic artery takeoff, and branching pattern of ophthalmic vasculature.

Results

Forty-four eyes from 33 patients with retinoblastoma treated with IAC were identified. Over the total 32 mean months of follow-up, these patients received 144 total catheterizations and a mean of 3.2 IAC cycles for each eye. The number of IAC cycles and the chemotherapeutic agent used did not vary significantly with worsening International Classification of Retinoblastoma (ICRB) groups (P > 0.1). Cumulative dose did not vary with the ICRB group for eyes treated with melphalan, topotecan, or carboplatin (P > 0.1). A higher ICRB group was associated with a smaller mean ophthalmic artery diameter across all procedures (P = 0.016), and femoral artery diameter did not vary significantly between ICRB groups (P = 0.906). A higher cumulative dose of IAC was significantly associated with a smaller takeoff angle of the OA (melphalan, P = 0.011; topotecan, P = 0.009; carboplatin, P = 0.031) in patients who underwent successful IAC procedures. Ophthalmic artery diameter and femoral artery diameter did not have a significant association (P > 0.1) with higher IAC doses in successful IACs. Cumulative IAC dose was not significantly associated with ophthalmic vasculature branching pattern, presence of choroidal blush, temporary OA vasospasm reported during the procedure, and OA occlusion upon microcatheter placement.

Conclusion

In this study, neurosurgical angioanatomy appeared to influence the cumulative dose of chemotherapy needed during IAC for retinoblastoma. In the future, these anatomic variables may be used to guide the frequency of monitoring, dosing, and estimation of recurrence risk.
Literatur
1.
Zurück zum Zitat Grigorovski N, Lucena E, Mattosinho C et al (2014) Use of intra-arterial chemotherapy for retinoblastoma: results of a survey. Int J Ophthalmol 7(4):726–730PubMedPubMedCentral Grigorovski N, Lucena E, Mattosinho C et al (2014) Use of intra-arterial chemotherapy for retinoblastoma: results of a survey. Int J Ophthalmol 7(4):726–730PubMedPubMedCentral
2.
Zurück zum Zitat Francis JH, Levin AM, Zabor EC, Gobin YP, Abramson DH (2018) Ten-year experience with ophthalmic artery chemosurgery: ocular and recurrence-free survival. PLoS One 13(5):e0197081CrossRefPubMedPubMedCentral Francis JH, Levin AM, Zabor EC, Gobin YP, Abramson DH (2018) Ten-year experience with ophthalmic artery chemosurgery: ocular and recurrence-free survival. PLoS One 13(5):e0197081CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Chen Q, Zhang B, Dong Y et al (2018) Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. BMC Cancer 18:486CrossRefPubMedPubMedCentral Chen Q, Zhang B, Dong Y et al (2018) Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. BMC Cancer 18:486CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Biancotto C, Shields CL, Iturralde JC, Sarici A, Jabbour P, Shields JA (2012) Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology 119(4):843–849CrossRef Biancotto C, Shields CL, Iturralde JC, Sarici A, Jabbour P, Shields JA (2012) Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology 119(4):843–849CrossRef
5.
Zurück zum Zitat Reddy MA, Naeem Z, Duncan C et al (2017) Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. Br J Ophthalmol 101(12):1704–1708CrossRefPubMed Reddy MA, Naeem Z, Duncan C et al (2017) Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. Br J Ophthalmol 101(12):1704–1708CrossRefPubMed
6.
Zurück zum Zitat Yamane T, Kaneko A, Mohri M (2004) The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 9(2):69–73CrossRefPubMed Yamane T, Kaneko A, Mohri M (2004) The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 9(2):69–73CrossRefPubMed
7.
Zurück zum Zitat Suzuki S, Kaneko A (2004) Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol 9(1):1–615162819CrossRefPubMed Suzuki S, Kaneko A (2004) Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol 9(1):1–615162819CrossRefPubMed
8.
Zurück zum Zitat Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP (2008) A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 115(8):1398–404, 1404.e1CrossRefPubMed Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP (2008) A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 115(8):1398–404, 1404.e1CrossRefPubMed
9.
Zurück zum Zitat Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP (2010) Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 117(8):1623–1629CrossRefPubMed Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP (2010) Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 117(8):1623–1629CrossRefPubMed
10.
Zurück zum Zitat Shields CL, Bianciotto CG, Jabbour P et al (2011) Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 129(11):1399–406CrossRefPubMed Shields CL, Bianciotto CG, Jabbour P et al (2011) Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 129(11):1399–406CrossRefPubMed
11.
Zurück zum Zitat Shields CL, Kaliki S, Shah SU et al (2012) Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Ophthalmology 119(1):188–192CrossRefPubMed Shields CL, Kaliki S, Shah SU et al (2012) Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Ophthalmology 119(1):188–192CrossRefPubMed
12.
Zurück zum Zitat Yousef YA, Soliman SE, Astudillo PPP et al (2016) Intra-arterial chemotherapy for retinoblastoma: a systematic review. JAMA Ophthalmol 134(5):584–591CrossRefPubMed Yousef YA, Soliman SE, Astudillo PPP et al (2016) Intra-arterial chemotherapy for retinoblastoma: a systematic review. JAMA Ophthalmol 134(5):584–591CrossRefPubMed
13.
Zurück zum Zitat Shields CL, Manjandavida FP, Lally SE et al (2014) Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology 121(7):1453–1460CrossRefPubMed Shields CL, Manjandavida FP, Lally SE et al (2014) Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology 121(7):1453–1460CrossRefPubMed
14.
Zurück zum Zitat Abramson DH, Marr BP, Dunkel IJ et al (2012) Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 96:499–502CrossRefPubMed Abramson DH, Marr BP, Dunkel IJ et al (2012) Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 96:499–502CrossRefPubMed
15.
Zurück zum Zitat Marr BP, Hung C, Gobin YP, Dunkel IJ, Brodie SE, Abramson DH (2012) Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy. Arch Ophthalmol 130(2):180–185CrossRefPubMed Marr BP, Hung C, Gobin YP, Dunkel IJ, Brodie SE, Abramson DH (2012) Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy. Arch Ophthalmol 130(2):180–185CrossRefPubMed
16.
Zurück zum Zitat Francis JH, Levin AM, Zabor EC et al (2018) Ten-year experience with ophthalmic artery chemosurgery: ocular and recurrence-free survival. PLoS ONE 13:e0197081CrossRefPubMedPubMedCentral Francis JH, Levin AM, Zabor EC et al (2018) Ten-year experience with ophthalmic artery chemosurgery: ocular and recurrence-free survival. PLoS ONE 13:e0197081CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Stenzel E, Göricke S, Temming P et al (2019) Feasibility of intra-arterial chemotherapy for retinoblastoma: experiences in a large single center cohort study. Neuroradiology 61:351–357CrossRefPubMed Stenzel E, Göricke S, Temming P et al (2019) Feasibility of intra-arterial chemotherapy for retinoblastoma: experiences in a large single center cohort study. Neuroradiology 61:351–357CrossRefPubMed
18.
Zurück zum Zitat Area C, Yen CJ, Chevez-Barrios P et al (2019) Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma. J NeuroInterv Surg 11:1273–1276CrossRefPubMed Area C, Yen CJ, Chevez-Barrios P et al (2019) Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma. J NeuroInterv Surg 11:1273–1276CrossRefPubMed
19.
Zurück zum Zitat Sweid A, Hammoud B, Weinberg JH et al (2020) Ophthalmic artery catheterization for retinoblastoma treatment: does reflux affect tumor response? J NeuroInterv Surg 12:915–920CrossRefPubMed Sweid A, Hammoud B, Weinberg JH et al (2020) Ophthalmic artery catheterization for retinoblastoma treatment: does reflux affect tumor response? J NeuroInterv Surg 12:915–920CrossRefPubMed
20.
Zurück zum Zitat Sweid A, El Naamani K, Sajja KC et al (2021) Incidence and predictors of ophthalmic artery occlusion in intra-arterial chemotherapy for retinoblastoma. J NeuroInterv Surg 13:652–656CrossRefPubMed Sweid A, El Naamani K, Sajja KC et al (2021) Incidence and predictors of ophthalmic artery occlusion in intra-arterial chemotherapy for retinoblastoma. J NeuroInterv Surg 13:652–656CrossRefPubMed
21.
Zurück zum Zitat Zhou M, Wen X, Jia S et al (2022) Risk factors for ophthalmic artery stenosis and occlusion in patients with retinoblastoma treated with intra-arterial chemotherapy. Br J Ophthalmol 106:1581–1586CrossRefPubMed Zhou M, Wen X, Jia S et al (2022) Risk factors for ophthalmic artery stenosis and occlusion in patients with retinoblastoma treated with intra-arterial chemotherapy. Br J Ophthalmol 106:1581–1586CrossRefPubMed
22.
Zurück zum Zitat Kim RS, Dannenbaum MJ, Lin MW, Bretana ME, Brown DL, Schefler AC (2018) Use of femoral artery ultrasound during intraarterial chemotherapy for children under 10 kg with retinoblastoma. Retina 38(7):1420–1426CrossRefPubMed Kim RS, Dannenbaum MJ, Lin MW, Bretana ME, Brown DL, Schefler AC (2018) Use of femoral artery ultrasound during intraarterial chemotherapy for children under 10 kg with retinoblastoma. Retina 38(7):1420–1426CrossRefPubMed
23.
Zurück zum Zitat Klufas MA, Gobin YP, Marr B et al (2012) Intra-arterial chemotherapy as a treatment for intraocular retinoblastoma: alternatives to direct ophthalmic artery catheterization. AJNR Am J Neuroradiol 33:1608–1614CrossRefPubMedPubMedCentral Klufas MA, Gobin YP, Marr B et al (2012) Intra-arterial chemotherapy as a treatment for intraocular retinoblastoma: alternatives to direct ophthalmic artery catheterization. AJNR Am J Neuroradiol 33:1608–1614CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Bertelli E, Leonini S, Galimberti D et al (2016) Hemodynamic and anatomic variations require an adaptable approach during intra-arterial chemotherapy for intraocular retinoblastoma: alternative routes, strategies, and follow-up. AJNR Am J Neuroradiol 37:1289–1295CrossRefPubMedPubMedCentral Bertelli E, Leonini S, Galimberti D et al (2016) Hemodynamic and anatomic variations require an adaptable approach during intra-arterial chemotherapy for intraocular retinoblastoma: alternative routes, strategies, and follow-up. AJNR Am J Neuroradiol 37:1289–1295CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Gobin YP, Dunkel IJ, Marr BP et al (2011) Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129:732–737CrossRefPubMed Gobin YP, Dunkel IJ, Marr BP et al (2011) Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129:732–737CrossRefPubMed
Metadaten
Titel
Angiographic characteristics and treatment approach in patients undergoing intra-arterial chemotherapy for retinoblastoma
verfasst von
Alexander M. Rusakevich
Michael I. Nahhas
Brenda Zhou
Mark J. Dannenbaum
Maria E. Bretana
Amy C. Schefler
Publikationsdatum
30.11.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 4/2024
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-023-06279-8

Weitere Artikel der Ausgabe 4/2024

Graefe's Archive for Clinical and Experimental Ophthalmology 4/2024 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.